1. Introduction {#sec0001}
===============

Even though fractional-order calculus (FOC) and differential equations (FODEs) have nearly the same history as those of ordinary differential equations (ODEs), they did not attract much attention till recent decades [@bib0001]. FOC, expressed as a generalization of ordinary differentiation and integration to arbitrary non-integer order and extensively used in different fields of science recently, is a branch of mathematical analysis \[[@bib0002],[@bib0003]\]. Most important feature of FOC is memory concept. If the output of a system at each time *t* depends only on the input at time *t*, then such systems are said to be memoryless systems. Otherwise, if the system has to remember previous values of the input to specify the current value of the output, then such systems are called memory systems [@bib0004]. In modeling of various memory phenomena, it is mentioned that a memory process usually consists of two stages. One is short with permanent retention, and the other is governed by a simple model of fractional derivative [@bib0005]. Numerous literature has been developed on the applications of FODEs and their systems (FOSs), a new and powerful tool that has recently been employed to model complex structures with nonlinear behavior and long-term memory [@bib0006], [@bib0007], [@bib0008]. Especially, biological systems are also rich source for mathematical modeling through FOSs [@bib0009].

Considering the recent mathematical modeling process of diseases, many scientists have used FOC and FODEs to describe different variety of diseases such as Ebola [@bib0010], tuberculosis [@bib0011], hepatitis [@bib0012], dengue fever [@bib0013], MERS-Cov [@bib0014], chickenpox [@bib0015], Zika virus [@bib0016], measles [@bib0017], rubella [@bib0018], etc. Moreover, the modelling of epidemic diseases assits understanding the main mechanisms effecting the spread of the disease, so that the control strategies are proposed through the modeling process [@bib0019]. These models are combined under two main headings, as the first is modeling the spread of infected individuals in a population [@bib0020] and the second is modeling the density of the infectious pathogen such as virus, bacteria, etc. in an individual \[[@bib0021],[@bib0022]\] as in this paper.

Viruses are the main cause of common human diseases such as influenza, cold, chicken pox and cold sores. Currently, there exist 21 families of viruses expressed to cause diseases in humans. Some of these diseases are very seriously infectious diseases such as *AIDS* (acquired immuno deficiency syndrome), Hepatitis, Herpes Simplex, Measles, avian influenza, *SARS* and *SARS*- or *MERS*-like coronavirus [@bib0023]. They have common features, such as they are all highly pathogenic to humans or livestock [@bib0024]. In particular *AIDS*, most severe stage of *HIV* (human immunodeficiency virus) infection, is remarkable as a fatal disease [@bib0025]. Considering the World Health Organization\'s report on the global situation and *HIV*/*AIDS* trends in 2018, there was globally about 37.9 million people living with *HIV*, 23.3 million people accessed antiretroviral therapy, 1.7 million people newly became infected with *HIV* and 770 thousand people died from *AIDS*-related illnesses [@bib0026]. *HIV* spreads only through certain body fluids such as blood, semen, pre-seminal fluids, rectal fluids, vaginal fluids, and breast milk, from an *HIV*-infected person. The immune response plays an important role to control the dynamics of viral infections such as *HIV* [@bib0021]. Mathematical models aimed to understand the host-virus interaction in case of *HIV* can supply non-intuitive information about the dynamics of the host response to the viruses and they can also offer new ways for the theraphy. In recent years, the *HIV* models with cure rate has received a great deal of attention.

A general mathematical model considered the basic dynamics of virus-host cell interaction was developed by Nowak et al. in [@bib0027]. In their study, they formulated the *HIV* model by using the following ODEs:$$\begin{array}{l}
{\frac{dx}{dt} = \lambda - dx - \beta xv} \\
{\frac{dy}{dt} = \beta xv - ay - \rho yz} \\
\begin{matrix}
{\frac{dv}{dt} = ky - uv} \\
{\frac{dz}{dt} = cyz - bz} \\
\end{matrix} \\
\end{array}$$with positive initial conditions. In here, *x*(*t*), *y*(*t*), *v*(*t*), and *z*(*t*) are the concentrations of uninfected (susceptible) host cells, infected host cells, free viruses, and *CTL* cells at time *t*, respectively. The production of uninfected cells is at a constant rate, *λ*. When uninfected cells encounter with free virus particles, they become infected at a rate *βxv. d* and *b* are rates of the natural death of uninfected cells and *CTL* cells, respectively. The infected cells die at an additional rate *ay*, which is the viral caused cell death (cytopathicity or cytotoxicity). Infected cells produce new virus particles with a rate *ky*, and the free virus particles that have been released from the cells decay with a rate *u*. The proliferation rate of *CTL* cells in the presence of infected cells is *c*. Finally, *CTL* cells cleans infected cells with the ratio *ρ* from the host. They explained the stabilities of the infection-free equilibrium and the positive equilibrium according to the basic reproduction number of the virus. Thus, they stimulated a model to work, aimed at interpreting experimental data, and led to the development of a new field of study called as viral dynamics.

Considering Eqs. [(1)](#eqn0001){ref-type="disp-formula"}, several nonlinear models, given in \[[@bib0028],[@bib0029]\] through ODEs and \[[@bib0012],[@bib0021],[@bib0030], [@bib0031], [@bib0032], [@bib0033]\] through FODEs, were studied by researchers. In this sense, they analyzed qualitatively and/or numerically their models by developing Eqs. [(1)](#eqn0001){ref-type="disp-formula"} under various assumptions. Also, these models include 3-dimensional time-dependent variables, where *T*(*t*), *I*(*t*) and *V*(*t*) represents the concentration of healthy $CD4 + \mspace{6mu} T$-cells at time *t*, the concentration of infected $CD4 + \mspace{6mu} T$-cells at time *t* and the concentration of free *HIV* at time *t*, respectively.

Mascio et al. [@bib0034] also considered the effect of antiviral drugs for Eqs. [(1)](#eqn0001){ref-type="disp-formula"}, and so, the efficacy of these drugs was estimated by mathematical modeling for retroviruses such as $HIV - 1$. While a protease inhibitor causes infected cells to produce immature non-infectious virus particles, a reverse transcriptase inhibitor effectively blocks the successful infection of a cell. In this sense, they assumed that when an antiretroviral drug such as a protease inhibitor or a reverse transcriptase inhibitor are applied to a patient in steady state as the viral load falls. To model this fall, the effectiveness of the drug is introduced into the model. Therefore, the virus dynamics is reformed to the following ODEs:$$\begin{array}{l}
{\frac{dx}{dt} = \lambda - dx - \left( {1 - \epsilon_{RT}} \right)\beta xv_{I}} \\
{\frac{dy}{dt} = \left( {1 - \epsilon_{RT}} \right)\beta xv_{I} - ay} \\
\begin{array}{l}
{\frac{dv_{I}}{dt} = \left( {1 - \epsilon_{PI}} \right)ky - uv_{I}} \\
{\frac{dv_{NI}}{dt} = \epsilon_{PI}ky - uv_{NI}} \\
\end{array} \\
\end{array}$$with positive initial conditions. Also, $\epsilon_{RT}$ and $\epsilon_{PI}$ are the efficacies of the reverse transcriptase inhibitor and protease inhibitor, respectively, and *v~I~* and *v~NI~*, denote infectious and non-infectious virions, respectively. This division of virions is because of the use of protease inhibitors. They performed stability analysis of the equilibrium points of their model. Based on Eqs. [(2)](#eqn0002){ref-type="disp-formula"}, several nonlinear models given in [@bib0035], [@bib0036], [@bib0037] through ODEs and \[[@bib0038],[@bib0039]\] through FODEs have been developed to describe the dynamics of the $HIV - 1$ virus, which take into account the dynamics of the *HIV* infection through antiretroviral therapies with different cell populations.

According to the derivative-orders in the system, FOSs can be considered in two parts commensurate and incommensurate and commensurate FOSs is a special case of incommensurate FOSs. Therefore, studies on incommensurate FOSs as in [@bib0040], [@bib0041], [@bib0042], [@bib0043], [@bib0044], [@bib0045], [@bib0046], [@bib0047], [@bib0048], [@bib0049], [@bib0050], [@bib0051], [@bib0052] are increasingly included in the literature.

The proposed model in this study has the following innovations:•It is assumed that both the infected cells and free virus particles have cleared by *CTL* cells and some neutralizing antibodies. Also, immune system cells have logistic growth rules.•Model has created by using a incommensurate FOS in Caputo sense.•In model, infected cells die at an additional rate called as the natural death rate.

In the qualitative analysis, specific conditions on the development of host cells (infected / uninfected) and viral particles (infectious / non-infectious) are obtained, which are under the pressure of the *CTL* response of the host and inhibitors. Additionally, the numerical simulations of the model are given as a detailed description of the dynamical behaviors of the proposed system. To do aforementioned, the rest of the paper is organized as follows.•In Section II, some preliminary definitions related to fractional derivative operators are described. The asymptotic stability conditions of the equilibrium point not only for incommensurate but also for commensurate FOSs are given.•The Section III presents the mathematical formulation of the proposed *HIV* infection model.•The Section IV discusses biological existence of the equilibrium points for the proposed model as well as its stability analysis.•Section V suggests numerical simulations to support the qualitative analysis results of the proposed FOS.•In Section VI, the paper finishes with some concluding remarks.

2. Preliminaries and definitions {#sec0002}
================================

  Definition 2.1Based on Riemann-Liouville definition, the *α*-th (*α* \> 0) order fractional derivative of function *f*(*t*) with respect to *t* is given by$$\frac{d^{\alpha}f\left( t \right)}{dt^{\alpha}} = \frac{1}{\Gamma\left( {m - \alpha} \right)}\frac{d^{m}}{dt^{m}}\int\limits_{0}^{t}\left( {t - \tau} \right)^{m - \alpha - 1}f\left( \tau \right)d\tau,$$ where *m* is the first integer larger than *α* such that $m - 1 \leq \alpha < m$ [@bib0053].

  Definition 2.2Considering the Caputo sense definition, the *α*-th (*α* \> 0) order fractional derivative of function *f*(*t*) with respect to *t* is described as the following:$$\frac{d^{\alpha}f\left( t \right)}{dt^{\alpha}} = \left\{ \begin{array}{l}
{\frac{1}{\Gamma\left( {m - \alpha} \right)}\int\limits_{0}^{t}\frac{f^{(m)}\left( \tau \right)}{\left( {t - \tau} \right)^{\alpha - m + 1}}d\tau\mspace{6mu} for\mspace{6mu} m - 1 < \alpha < m} \\
{\frac{d^{m}f\left( t \right)}{dt^{m}}\mspace{6mu} for\mspace{6mu}\alpha = m} \\
\end{array} \right.$$ where *m* is the first integer larger than *α* [@bib0054].

In the rest of this paper, the notation $\frac{d^{\alpha}}{dt^{\alpha}}$ represents the Caputo fractional derivative of order *α*.

  Remark 2.1In this paper, we have consider the following nonlinear FOS:$$\frac{d^{\overline{\alpha}}X\left( t \right)}{dt^{\overline{\alpha}}} = F\left( {t,X\left( t \right)} \right),$$ with suitable initial conditions $X\left( 0 \right) = X_{0}$, where $X\left( t \right) = \left\lbrack {x_{1}\left( t \right),\mspace{6mu} x_{2}\left( t \right),\ldots,\mspace{6mu} x_{n}\left( t \right)} \right\rbrack^{T} \in \mathbb{R}^{n}$ is the state vectors of Eqs [(5)](#eqn0005){ref-type="disp-formula"}, $F = \left\lbrack {f_{1},\mspace{6mu} f_{2},\ldots,\mspace{6mu} f_{n}} \right\rbrack^{T} \in \mathbb{R}^{n}$, $\left. f_{i}{:\mspace{6mu}\left\lbrack \left. {0, + \infty} \right)x \right.}\mathbb{R}^{n}\rightarrow\mathbb{R} \right.$, $\left( {i = 1,2,\ldots,n} \right)$, $\overline{\alpha} = \left\lbrack {\alpha_{1},\mspace{6mu}\alpha_{2},\ldots,\mspace{6mu}\alpha_{n}} \right\rbrack^{T}$ is the multi-order of Eqs [(5)](#eqn0005){ref-type="disp-formula"}, $\frac{d^{\overline{\alpha}}X\left( t \right)}{dt^{\overline{\alpha}}} = \left\lbrack {\frac{d^{\alpha_{1}}x_{1}\left( t \right)}{dt^{\alpha_{1}}},\mspace{6mu}\frac{d^{\alpha_{2}}x_{2}\left( t \right)}{dt^{\alpha_{2}}},\ldots,\frac{d^{\alpha_{n}}x_{n}\left( t \right)}{dt^{\alpha_{n}}}} \right\rbrack^{T}$ [@bib0047].

Throughout rest of the paper, it has been accepted that *α~i~* is a rational number in the interval (0, 1\|.

  Definition 2.3In particular, if $\alpha_{1} = \alpha_{2} = \ldots = \alpha_{n} = \alpha$, then Eqs [(5)](#eqn0005){ref-type="disp-formula"} can be written as$$\frac{d^{\alpha}X\left( t \right)}{dt^{\alpha}} = F\left( {t,X\left( t \right)} \right).$$

We call Eqs [(6)](#eqn0006){ref-type="disp-formula"} as the commensurate FOS, otherwise, call Eqs. [(5)](#eqn0005){ref-type="disp-formula"} as incommensurate FOS [@bib0045].

  Definition 2.4The autonomous form of incommensurate FOS in Eqs. [(5)](#eqn0005){ref-type="disp-formula"} is shown as$$\frac{d^{\overline{\alpha}}X\left( t \right)}{dt^{\overline{\alpha}}} = F\left( {X\left( t \right)} \right),$$ with initial conditions $X\left( 0 \right) = X_{0}$. Also, the equilibrium point of Eqs. [(7)](#eqn0007){ref-type="disp-formula"} is the point $\overline{X} = \left( {\overline{x_{1}},\overline{x_{2}},\ldots,\overline{x_{n}}} \right)$ obtained from equations $F\left( \overline{X} \right) = 0$.

  Lemma 2.1Eigenvalues *λ~i~* for $i = 1,2,\ldots,\mspace{6mu} m\left( {\alpha_{1} + \mspace{6mu}\alpha_{2} + \ldots + \alpha_{n}} \right)$ of Eqs [(7)](#eqn0007){ref-type="disp-formula"} are obtained from the charasteristic equation given as$$det\left( {diag\left( {\lambda^{m\alpha_{1}},\mspace{6mu}\lambda^{m\alpha_{2}},\ldots,\lambda^{m\alpha_{n}}} \right) - \mspace{6mu} J\left( \overline{X} \right)} \right) = 0$$ where *m* is the smallest of the common multiples of the denominators of rational numbers $\alpha_{1},\mspace{6mu}\alpha_{2},\ldots,\mspace{6mu}\alpha_{n}$ and $J\left( \overline{X} \right) = {\frac{\partial F}{\partial X}|_{X = \overline{X}}}$. If all eigenvalues *λ~i~* obtained from [Eq. (8)](#eqn0008){ref-type="disp-formula"} satisfy$$\left| {arg\left( \lambda_{i} \right)} \right| > \frac{\pi}{2m},$$then $\overline{X}$ is asymptotically stable for incommensurate FOS in Eqs. [(7)](#eqn0007){ref-type="disp-formula"} [@bib0055].

The stable and unstable regions for incommensurate and commensurate forms of Eqs. [(7)](#eqn0007){ref-type="disp-formula"} are shown in [Fig. 1](#fig0001){ref-type="fig"}, [Fig. 2](#fig0002){ref-type="fig"} .Fig. 1The stable and unstable regions for incommensurate FOS in Eqs. [(7)](#eqn0007){ref-type="disp-formula"}.Fig 1Fig. 2The stable and unstable regions for commensurate FOS form of Eqs. [(7)](#eqn0007){ref-type="disp-formula"}.Fig 2

According to some special cases of fractional derivative orders, the stability analysis has summarized below:iLet $\alpha_{1} = \mspace{6mu}\alpha_{2} = \ldots = \alpha_{n} = \alpha < 1$ in Eqs [(7)](#eqn0007){ref-type="disp-formula"}. If all eigenvalues *λ~i~* for $i = 1,2,\ldots,n$ obtained from$$Det\left( {\mspace{6mu}\lambda I_{nxn} - J\left( \overline{X} \right)} \right) = 0$$satisfies either the Routh--Hurwitz stability conditions or the following conditions:$$\left| {arg\left( \lambda_{i} \right)} \right| > \frac{\alpha\pi}{2}\mspace{6mu} for\mspace{6mu} i = 1,2,\ldots n,$$then $\overline{X}$ is asymptotically stable point [@bib0056]. Here, the matrix *I~nxn~* is an identity matrix.

Additionally, the charasteristic equation obtained from [Eq. (10)](#eqn0010){ref-type="disp-formula"} can be showed by$$P\left( \lambda \right) = \lambda^{n} + a_{1}\lambda^{n - 1} + \ldots + a_{n - 1}\lambda + a_{n},$$where coefficients *a~i~* for $i = 1,...,n$ are real constants. The Routh-Hurwitz stability conditions for polynomial of degree $n = 2$ and 3 can be summarized as$$\begin{array}{lc}
{a_{1},a_{2} > 0} & {for\mspace{6mu} n = 2} \\
{a_{1},a_{3} > 0\mspace{6mu}{\text{and}\mspace{6mu}}a_{1}a_{2} > a_{3}} & {for\mspace{6mu} n = 3.} \\
\end{array}$$

Above mentioned criteria has supplied necessary and sufficient conditions for all roots of *P*(*λ*) to lie in the left half of the complex plane [@bib0057].iLet $\alpha_{1} = \mspace{6mu}\alpha_{2} = \ldots = \alpha_{n} = 1$ in Eqs [(7)](#eqn0007){ref-type="disp-formula"}. It is presumed that the characteristic equation is as showing in [Eq. (12)](#eqn0012){ref-type="disp-formula"}. If all eigenvalues *λ~i~* for $i = 1,2,\ldots,n$ obtained from [Eq. (12)](#eqn0012){ref-type="disp-formula"} satisfy Routh-Hurwitz stability conditions, then $\overline{X}$ is asymptotically stable point [@bib0058].

3. The *HIV* model through incommensurate FOS {#sec0003}
=============================================

In this study, the new *HIV* infection model in an individual based on [Eqs. (1)](#eqn0001){ref-type="disp-formula"} and [(2)](#eqn0002){ref-type="disp-formula"} have been analyzed by incommensurate FOS. Let us denote by *x*(*t*) population size of uninfected (or susceptible) cells of host at time *t*, by *y*(*t*) population size of the emerged infected cells when *x*(*t*) meet free viruses at time *t*, by *v~I~*(*t*) population size of the infectious viral particles concentration at time *t*, by *v~NI~*(*t*) population size of the noninfectious viral particles concentration at time *t* and by *z*(*t*) population size of *CTL* response of host at time *t*. The recruitment of *CTL* responses have been classically associated with the control of *HIV* replication and *CTL* is very important for the clearance of *HIV*. The newly produced virus particles are separated into two parts as *v~I~*(*t*) and *v~NI~*(*t*), to analyze the effect of protease inhibitor. Therefore, we have incommensurate FOS given by$$\begin{array}{l}
{\frac{d^{\alpha_{1}}x\left( t \right)}{dt^{\alpha_{1}}} = \gamma - \rho x - \left( {1 - \epsilon_{RT}} \right)\beta xv_{I}} \\
{\frac{d^{\alpha_{2}}y\left( t \right)}{dt^{\alpha_{2}}} = \left( {1 - \epsilon_{RT}} \right)\beta xv_{I} - \left( {\rho + \omega} \right)y - \delta yz} \\
\begin{array}{l}
{\frac{d^{\alpha_{3}}v_{I}\left( t \right)}{dt^{\alpha_{3}}} = \left( {1 - \epsilon_{PI}} \right)ky - uv_{I} - \sigma v_{I}z} \\
{\frac{d^{\alpha_{4}}v_{NI}\left( t \right)}{dt^{\alpha_{4}}} = \epsilon_{PI}ky - uv_{NI} - \sigma v_{NI}z} \\
{\frac{d^{\alpha_{5}}z\left( t \right)}{dt^{\alpha_{5}}} = rz\left( {1 - \frac{z}{C}} \right)} \\
\end{array} \\
\end{array}$$where *t* ≥ 0, *α~i~* ∈ (0, 1\] for $i = 1,2,\ldots,5$ and the parameters have the properties given as$$\begin{array}{l}
{\gamma,\mspace{6mu}\rho,\mspace{6mu}\beta,\mspace{6mu}\omega,\mspace{6mu}\delta,\mspace{6mu} k,\mspace{6mu} u,\mspace{6mu}\sigma,\mspace{6mu} r,C \in \mathbb{R}^{+}} \\
{0 < \epsilon_{RT} < 1\mspace{6mu}\text{and}\mspace{6mu} 0 < \epsilon_{PI} < 1} \\
\end{array}$$

We also have positive initial conditions $x\left( t_{0} \right) = x_{0}$, $y\left( t_{0} \right) = y_{0}$, $v_{I}\left( t_{0} \right) = {v_{I}}_{0}$, $v_{NI}\left( t_{0} \right) = {v_{NI}}_{0}$ and $z\left( t_{0} \right) = z_{0}$. The meanings of biological parameters in [Eqs. (14)](#eqn0014){ref-type="disp-formula"} are given in [Table 1](#tbl0001){ref-type="table"} .Table 1Meanings of parameters used in [Eqs. (14)](#eqn0014){ref-type="disp-formula"}.Table 1*γ*:Concentration of the uninfected target cells (*x*) produced at a constant rate*ρ*:Rate of natural death of uninfected cells and infected cells (*x* and *y*)*β*:Encounter rate of uninfected cells (*x*) with free virus particles (*v~I~*)$\epsilon_{RT}$:The efficacy of the therapy with reverse transcriptase inhibitors$\epsilon_{PI}$:The efficacy of the therapy with reverse protease inhibitors*δ*:Removed rate of infected cells by *CTL* cells*ω*:Rate of death of the infected cells due to cytopathicity or cytotoxicity of free virus particles*k*:Rate of the produce of new virus particles by infected cells*u*:Rate of natural death of viral particles*σ*:Removed rate of virus particles by *CTL* cells*r*:The proliferate rate of *CTL* cells*C*:The carrying capacity of *CTL* cells

The abovementioned scenario for [Eqs. (14)](#eqn0014){ref-type="disp-formula"} has been graphically demonstrated in [Fig. 3](#fig0003){ref-type="fig"} .Fig. 3Schematic demonstration of interaction among variables in [Eqs. (14)](#eqn0014){ref-type="disp-formula"}.Fig 3

4. Qualitative analysis of the proposed *HIV* model {#sec0004}
===================================================

In this section, the threshold parameters given as *R* ~0~ and *R* ~1~ are first introduced to ease the qualitative analysis. Then it is discussed the existence and stability of equilibrias of the model in [Eqs. (14)](#eqn0014){ref-type="disp-formula"}.

  Definition 4.1Let$$R_{0} = \frac{\gamma\beta k\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right)}{\rho\left( {u + \sigma C} \right)\left( {\rho + \omega + \delta C} \right)}\mspace{6mu}\text{and}\mspace{6mu} R_{1} = \frac{u\left( {\rho + \omega} \right)}{\left( {u + \sigma C} \right)\left( {\rho + \omega + \delta C} \right)}$$ for reduce the complexity of operations. Considering In Eqs. [(15)](#eqn0015){ref-type="disp-formula"}, it is clear that$$0 < R_{0}\mspace{6mu}\text{and}\mspace{6mu} 0 < R_{1} < 1.$$

In here, the *R* ~0~ threshold parameter, sometimes called basic reproduction rate or basic reproductive ratio, is used to measure the transmission potential of a disease. Biologically, this parameter is the average number of newly infected cells produced by a single infected cell when almost all cells are still uninfected. Also, the parameter *R* ~1~ has been given only to reduce the processing complexity in the analysis.

  Proposition 4.1According to the biological existence conditions of the equilibrium points of [Eqs. (14)](#eqn0014){ref-type="disp-formula"}, it is obtained the following results:i$E_{0}\left( {\frac{\gamma}{\rho},0,0,0,0} \right)$ always exists.ii$E_{1}\left( {\frac{\gamma R_{1}}{R_{0}\rho},\frac{\gamma\left( {R_{0} - R_{1}} \right)}{R_{0}\left( {\rho + \omega} \right)},\frac{\rho\left( {R_{0} - R_{1}} \right)}{\beta\left( {1 - \epsilon_{RT}} \right)R_{1}},\frac{\gamma k\epsilon_{PI}\left( {R_{0} - R_{1}} \right)}{R_{0}u\left( {\rho + \omega} \right)},0} \right)$ exists, when *R* ~0~ \> *R* ~1~.iii$E_{2}\left( {\frac{\gamma}{\rho},0,0,0,C} \right)$ is the infection-free equilibrium point and always exists.iv$E_{3}\left( {\frac{\gamma}{\rho}\frac{1}{R_{0}},\frac{\gamma}{\left\lbrack {\left( {\rho + \omega} \right) + \delta C} \right\rbrack}\left( {1 - \frac{1}{R_{0}}} \right),\frac{\rho\left( {R_{0} - 1} \right)}{\beta\left( {1 - \epsilon_{RT}} \right)},\frac{\rho\epsilon_{PI}\left( {R_{0} - 1} \right)}{\beta\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right)},C} \right)$ is the endemic equilibrium point and exists when *R* ~0~ \> 1.

In here, *R* ~0~ and *R* ~1~ are in [Definition 4.1](#enun0007){ref-type="statement"}.

  ProofThe steady state solution of [Eqs. (14)](#eqn0014){ref-type="disp-formula"} is a point $\left( {\overline{x},\mspace{6mu}\overline{y},\mspace{6mu}\overline{v_{I}},\mspace{6mu}\overline{v_{NI}},\mspace{6mu}\overline{z}} \right)$ satisfying the following equations: $\frac{d^{\alpha_{1}}x}{dt^{\alpha_{1}}} = 0$, $\frac{d^{\alpha_{2}}y}{dt^{\alpha_{2}}} = 0$, $\frac{d^{\alpha_{3}}v_{I}}{dt^{\alpha_{3}}} = 0$, $\frac{d^{\alpha_{4}}v_{NI}}{dt^{\alpha_{4}}} = 0$ and $\frac{d^{\alpha_{5}}z}{dt^{\alpha_{5}}} = 0$. Therefore, it is obtained the system given by$$\begin{array}{l}
{\gamma - \rho\overline{x} - \left( {1 - \epsilon_{RT}} \right)\beta\overline{x}\overline{v_{I}} = 0} \\
{\left( {1 - \epsilon_{RT}} \right)\beta\overline{x}\overline{v_{I}} - \left( {\rho + \omega} \right)\overline{y} - \delta\overline{y}\overline{z} = 0} \\
\begin{array}{l}
{\left( {1 - \epsilon_{PI}} \right)k\overline{y} - u\overline{v_{I}} - \sigma\overline{v_{I}}\overline{z} = 0} \\
{\epsilon_{PI}k\overline{y} - u\overline{v_{NI}} - \sigma\overline{v_{NI}}\overline{z} = 0} \\
{r\overline{z}\left( {1 - \frac{\overline{z}}{C}} \right) = 0.} \\
\end{array} \\
\end{array}$$

By fifth equation of [Eqs. (18)](#eqn0018){ref-type="disp-formula"}, it is $\overline{z} = 0$ or $\overline{z} = C$. Therefore we have the followings:a)Firstly, let $\overline{z} = 0$. Then,$$\overline{v_{I}} = \frac{\left( {1 - \epsilon_{PI}} \right)k}{u}\overline{y}\mspace{6mu}\text{and}\mspace{6mu}\overline{v_{NI}} = \frac{\epsilon_{PI}k}{u}\overline{y}$$are found from the third and fourth equations in [Eqs. (18)](#eqn0018){ref-type="disp-formula"}. If [Eqs. (19)](#eqn0019){ref-type="disp-formula"} are written their place in the first and second equations of [Eqs. (18)](#eqn0018){ref-type="disp-formula"}, then it is acquired equations given as$$\begin{array}{l}
{\gamma - \rho\overline{x} - \overline{x}\overline{y}\frac{\beta k\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right)}{u} = 0} \\
{\overline{y}\left( {\overline{x}\frac{\beta k\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right)}{u} - \left( {\rho + \omega} \right)} \right) = 0} \\
\end{array}$$

From the second equation of [Eqs. (20)](#eqn0020){ref-type="disp-formula"}, $\overline{y} = 0$ or $\overline{x} = \frac{u\left( {\rho + \omega} \right)}{\beta k\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right)}$ are obtained.iLet $\overline{y} = 0$. We have $\overline{x} = \frac{\gamma}{\rho}$ by first equation of [Eqs. (20)](#eqn0020){ref-type="disp-formula"} and $\overline{v_{I}} = \overline{v_{NI}} = 0$ by [Eqs. (19)](#eqn0019){ref-type="disp-formula"}. Hence, $E_{0}\left( {\frac{\gamma}{\rho},0,0,0,0} \right)$ is found. This point always exists, because it is $\frac{\gamma}{\rho} > 0$ in accordance with Ineqs [(15)](#eqn0015){ref-type="disp-formula"}.iiLet $\overline{x} = \frac{u\left( {\rho + \omega} \right)}{\beta k\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right)}$. It is obtained $\overline{y} = \left( \frac{\gamma\beta k\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right) - \rho u\left( {\rho + \omega} \right)}{\beta k\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right)\left( {\rho + \omega} \right)} \right)$ from the first equation of [Eqs. (20)](#eqn0020){ref-type="disp-formula"}. Therefore, it is $\overline{v_{I}} = \frac{\gamma\beta k\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right) - \rho u\left( {\rho + \omega} \right)}{\beta\left( {1 - \epsilon_{RT}} \right)u\left( {\rho + \omega} \right)}$ and $\overline{v_{NI}} = \epsilon_{PI}\left( \frac{\gamma\beta k\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right) - \rho u\left( {\rho + \omega} \right)}{\beta\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right)u\left( {\rho + \omega} \right)} \right)$ from [Eqs. (19)](#eqn0019){ref-type="disp-formula"}. Let us consider [Eqs. (16)](#eqn0016){ref-type="disp-formula"}. In this case, we have $E_{1}\left( {\frac{\gamma R_{1}}{R_{0}\rho},\frac{\gamma\left( {R_{0} - R_{1}} \right)}{R_{0}\left( {\rho + \omega} \right)},\frac{\rho\left( {R_{0} - R_{1}} \right)}{\beta\left( {1 - \epsilon_{RT}} \right)R_{1}},\frac{\gamma k\epsilon_{PI}\left( {R_{0} - R_{1}} \right)}{R_{0}u\left( {\rho + \omega} \right)},0} \right)$. If *R* ~0~ \> *R* ~1~, then *E* ~1~ exists in regard to Ineqs. [(15)](#eqn0015){ref-type="disp-formula"} and [(17)](#eqn0017){ref-type="disp-formula"}.b)On the other hand, let $\overline{z} = C$. [Eqs. (18)](#eqn0018){ref-type="disp-formula"} translates system given by$$\begin{array}{l}
{\gamma - \rho\overline{x} - \left( {1 - \epsilon_{RT}} \right)\beta\overline{x}\overline{v_{I}} = 0} \\
{\left( {1 - \epsilon_{RT}} \right)\beta\overline{x}\overline{v_{I}} - \left( {\rho + \omega} \right)\overline{y} - C\delta\overline{y} = 0} \\
\begin{array}{l}
{\left( {1 - \epsilon_{PI}} \right)k\overline{y} - u\overline{v_{I}} - C\sigma\overline{v_{I}} = 0} \\
{\epsilon_{PI}k\overline{y} - u\overline{v_{NI}} - C\sigma\overline{v_{NI}} = 0.} \\
\end{array} \\
\end{array}$$

The following equations:$$\overline{v_{I}} = \frac{\left( {1 - \epsilon_{PI}} \right)k}{\left( {u + C\sigma} \right)}\overline{y}\mspace{6mu}\text{and}\mspace{6mu}\overline{v_{NI}} = \frac{\epsilon_{PI}k}{\left( {u + C\sigma} \right)}\overline{y}$$is obtained from third and fourth equations in [(21)](#eqn0021){ref-type="disp-formula"}. When the equalities in [Eqs. (22)](#eqn0022){ref-type="disp-formula"} have rewritten in first and second equations of [(21)](#eqn0021){ref-type="disp-formula"},it is obtained the system given as$$\begin{array}{l}
{\gamma - \rho\overline{x} - \overline{x}\overline{y}\frac{\beta k\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right)}{\left( {u + C\sigma} \right)} = 0} \\
{\overline{y}\left( {\overline{x}\frac{\beta k\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right)}{\left( {u + C\sigma} \right)} - \left( {\left( {\rho + \omega} \right) + C\delta} \right)} \right) = 0} \\
\end{array}$$

By the second equation of [Eqs. (23)](#eqn0023){ref-type="disp-formula"}, it is either $\overline{y} = 0$ or $\overline{x} = \frac{\left( {\left( {\rho + \omega} \right) + C\delta} \right)\left( {u + C\sigma} \right)}{\beta k\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right)}$.iLet us consider as $\overline{y} = 0$. In this case, it is obtained the following equations: $\overline{v_{I}} = \overline{v_{NI}} = 0$ by [Eqs. (22)](#eqn0022){ref-type="disp-formula"} and $\overline{x} = \frac{\gamma}{\rho}$ by the first equation of [Eqs. (23)](#eqn0023){ref-type="disp-formula"}. Therefore, we obtain the equilibrium point $E_{2}\left( {\frac{\gamma}{\rho},0,0,0,C} \right)$. This equilibrium point is the infection-free equilibrium point and it exists always according to Ineqs [(15)](#eqn0015){ref-type="disp-formula"}.iiLastly, let $\overline{x} = \frac{\left( {\left( {\rho + \omega} \right) + C\delta} \right)\left( {u + C\sigma} \right)}{\beta k\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right)}$. Similarly to a)-ii, $\overline{v_{I}} = \frac{k\gamma\left( {1 - \epsilon_{PI}} \right)}{\left( {u + C\sigma} \right)\left( {\left( {\rho + \omega} \right) + C\delta} \right)}\left( {1 - \frac{\rho\left( {u + C\sigma} \right)\left( {\left( {\rho + \omega} \right) + C\delta} \right)}{\beta k\gamma\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right)}} \right)$, $\overline{v_{NI}} = \frac{k\gamma\epsilon_{PI}}{\left( {u + C\sigma} \right)\left( {\left( {\rho + \omega} \right) + C\delta} \right)}\left( {1 - \frac{\rho\left( {u + C\sigma} \right)\left( {\left( {\rho + \omega} \right) + C\delta} \right)}{\beta k\gamma\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right)}} \right)$ by [Eqs. (22)](#eqn0022){ref-type="disp-formula"} and $\overline{y} = \frac{\gamma}{\left( {\left( {\rho + \omega} \right) + C\delta} \right)}\left( {1 - \frac{\rho\left( {u + C\sigma} \right)\left( {\left( {\rho + \omega} \right) + C\delta} \right)}{\beta k\gamma\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right)}} \right)$ by the first equation of [Eqs (23)](#eqn0023){ref-type="disp-formula"} are found. If the threshold parameter *R* ~0~ in [Eqs. (16)](#eqn0016){ref-type="disp-formula"} is taken into consideration, then $E_{3}\left( {\frac{\gamma}{\rho}\frac{1}{R_{0}},\frac{\gamma\left( {1 - \frac{1}{R_{0}}} \right)}{\left\lbrack {\left( {\rho + \omega} \right) + \delta C} \right\rbrack},\frac{\rho\left( {R_{0} - 1} \right)}{\beta\left( {1 - \epsilon_{RT}} \right)},\frac{\rho\epsilon_{PI}\left( {R_{0} - 1} \right)}{\beta\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right)},C} \right)$, called as the endemic equilibrium point, is obtained. Considering Ineqs. [(15)](#eqn0015){ref-type="disp-formula"} and [(17)](#eqn0017){ref-type="disp-formula"}, if *R* ~0~ \> 1, then this point exists.

Thus, the Proposition is proved.

  Proposition 4.2Let us consider [Eqs. (14)](#eqn0014){ref-type="disp-formula"}. For all *α~i~*'s for $i = 1,2,\ldots,5$ are rational numbers between 0 and 1. Assume *m* be the lowest common multiple of the denominators *m~i~*'s of *α~i~*'s, where $\alpha_{i} = \frac{k_{i}}{m_{i}}$, $\left( {k_{i},m_{i}} \right) = 1$, $k_{i},m_{i}\epsilon\mathbb{Z}^{+}$. Under aforementioned assumptions, it is provided the followings:i*E* ~0~ is always unstable point.iiWhen *R* ~0~ \> *R* ~1~, *E* ~1~ exists. However, it is an unstable point under this condition.iiiLet us consider infection-free equilibrium point *E* ~2~, which always exists. It is obtained the following cases: • Let *α* ~2~ ≠  *α* ~3~ \< 1. If *R* ~0~ \< 1 and eigenvalues obtained from$$\begin{array}{ccl}
 & & {\lambda^{m{({\alpha_{2} + \alpha_{3}})}} + \left( {u + \sigma C} \right)\lambda^{m\alpha_{2}} + \left( {\left( {\rho + \omega} \right) + \delta C} \right)\lambda^{m\alpha_{3}}} \\
 & & {\quad + \,\left( {u + \sigma C} \right)\left( {\left( {\rho + \omega} \right) + \delta C} \right)\left( {1 - R_{0}} \right) = 0} \\
\end{array}$$ meet conditions given as $|{arg\left( \lambda_{n} \right)}\left| > \right.\frac{\pi}{2m}$ for $n = 1,2,\ldots,\mspace{6mu} m\left( {\mspace{6mu}\alpha_{2} + \alpha_{3}} \right)$, then it is asymptotically stable point for [Eqs. (14)](#eqn0014){ref-type="disp-formula"}.• Let $\alpha_{2} = \mspace{6mu}\alpha_{3} = \alpha \leq 1$. If *R* ~0~ \< 1, it is asymptotically stable point for [Eqs. (14)](#eqn0014){ref-type="disp-formula"}. iLet us consider endemic equilibrium point *E* ~3~, which exists for *R* ~0~ \> 1. The following cases are obtained. • Let *α* ~1~ ≠  *α* ~2~ ≠ *α* ~3~ \< 1. If eigenvalues obtained from$$\begin{array}{ccl}
 & & {\lambda^{m{({\alpha_{1} + \alpha_{2} + \alpha_{3}})}} + \left( {u + \sigma C} \right)\lambda^{m{({\alpha_{1} + \alpha_{2}})}} + \left( {\left( {\rho + \omega} \right) + \delta C} \right)\lambda^{m{({\alpha_{1} + \alpha_{3}})}}} \\
 & & {\quad + \,\rho R_{0}\lambda^{m{({\alpha_{2} + \alpha_{3}})}} + \rho R_{0}\left( {u + \sigma C} \right)\lambda^{m\alpha_{2}}} \\
 & & {\quad + \,\left( {\left( {\rho + \omega} \right) + \delta C} \right)\rho R_{0}\lambda^{m\alpha_{3}}} \\
 & & {\quad + \,\rho\left( {R_{0} - 1} \right)\left( {u + \sigma C} \right)\left( {\rho + \omega + \delta C} \right) = 0} \\
\end{array}$$meet conditions given by $|{arg\left( \lambda_{n} \right)}\left| > \right.\frac{\pi}{2m}$ for $n = 1,2,\ldots,\mspace{6mu} m\left( {\alpha_{1} + \mspace{6mu}\alpha_{2} + \alpha_{3}} \right)$, then it is asymptotically stable point for [Eqs. (14)](#eqn0014){ref-type="disp-formula"}.• Let $\alpha_{1} = \mspace{6mu}\alpha_{2} = \alpha_{3} = \alpha \leq 1$. It is asymptotically stable point for [Eqs. (14)](#eqn0014){ref-type="disp-formula"}.

  ProofTo perform stability analysis, the functions in [Eqs. (14)](#eqn0014){ref-type="disp-formula"} are determined by$$\begin{array}{l}
{\frac{d^{\alpha_{1}}x}{dt^{\alpha_{1}}} = f_{1}\left( {x,y,v_{I},v_{NI},z} \right) = \gamma - \rho x - \left( {1 - \int_{RT}} \right)\beta xv_{I}} \\
{\frac{d^{\alpha_{2}}y}{dt^{\alpha_{2}}} = f_{2}\left( {x,y,v_{I},v_{NI},z} \right) = \left( {1 - \varepsilon_{RT}} \right)\beta xv_{I} - \left( {\rho + \omega} \right)y - \delta yz} \\
{\frac{d^{\alpha_{3}}v_{I}}{dt^{\alpha_{3}}} = f_{3}\left( {x,y,v_{I},v_{NI},z} \right) = \left( {1 - \varepsilon_{PI}} \right)ky - uv_{I} - \sigma v_{I}z} \\
{\frac{d^{\alpha_{4}}v_{NI}}{dt^{\alpha_{4}}} = f_{4}\left( {x,y,v_{I},v_{NI},z} \right) = \varepsilon_{PI}ky - uv_{NI} - \sigma v_{NI}z} \\
{\frac{d^{\alpha_{5}}z}{dt^{\alpha_{5}}} = f_{5}\left( {x,y,v_{I},v_{NI},z} \right) = rz\left( {1 - \frac{z}{C}} \right).} \\
\end{array}$$

That jacobian matrix obtained from [Eqs. (24)](#eqn0024){ref-type="disp-formula"} is$$J = \begin{pmatrix}
{- \left( {\beta v_{I}\left( {1 - \epsilon_{RT}} \right) + \rho} \right)} & 0 & {- \beta x\left( {1 - \epsilon_{RT}} \right)} & 0 & 0 \\
{\beta v_{I}\left( {1 - \epsilon_{RT}} \right)} & {- \left( {\left( {\rho + \omega} \right) + \delta z} \right)} & {\beta x\left( {1 - \epsilon_{RT}} \right)} & 0 & {- \delta y} \\
0 & {k\left( {1 - \epsilon_{PI}} \right)} & {- \left( {u + \sigma z} \right)} & 0 & {- \sigma v_{I}} \\
0 & {k\epsilon_{PI}} & 0 & {- \left( {u + \sigma z} \right)} & {- \sigma v_{NI}} \\
0 & 0 & 0 & 0 & {r\left( {1 - 2\frac{z}{C}} \right)} \\
\end{pmatrix}.$$

For the jacobian matrix evaluated at equilibrium point $E_{j}\left( {\overline{x},\mspace{6mu}\overline{y},\mspace{6mu}\overline{v_{I}},\mspace{6mu}\overline{v_{NI}},\mspace{6mu}\overline{z}} \right)$ for $j = 0,1,2,3$, the characteristic equation have found from$$\begin{array}{r}
{\left( {\lambda^{m\alpha_{4}} + \left( {u + \sigma\overline{z}} \right)} \right)\left( {\lambda^{m\alpha_{5}} - r\left( {1 - 2\frac{\overline{z}}{C}} \right)} \right)\left| \begin{matrix}
{\lambda^{m\alpha_{1}} + \left( {\beta\overline{v_{I}}\left( {1 - \epsilon_{RT}} \right) + \rho} \right)} & 0 & {\beta\overline{x}\left( {1 - \epsilon_{RT}} \right)} \\
{- \beta\overline{v_{I}}\left( {1 - \epsilon_{RT}} \right)} & {\lambda^{m\alpha_{2}} + \left( {\left( {\rho + \omega} \right) + \delta\overline{z}} \right)} & {- \beta\overline{x}\left( {1 - \epsilon_{RT}} \right)} \\
0 & {- k\left( {1 - \epsilon_{PI}} \right)} & {\lambda^{m\alpha_{3}} + \left( {u + \sigma\overline{z}} \right)} \\
\end{matrix} \right| = 0.\mspace{10370mu}} \\
\end{array}$$with respect to $det\left( {diag\left( {\lambda^{m\alpha_{1}},\mspace{6mu}\lambda^{m\alpha_{2}},\lambda^{m\alpha_{3}},\lambda^{m\alpha_{4}},\lambda^{m\alpha_{5}}} \right) - J\left( E_{j} \right)} \right)$.iBy [Eq. (25)](#eqn0025){ref-type="disp-formula"} calculated at $E_{0}\left( {\frac{\gamma}{\rho},0,0,0,0} \right)$, some of the eigenvalues are achieved from equations given as $\lambda^{m\alpha_{1}} = - \rho,\mspace{6mu}\lambda^{m\alpha_{4}} = - u$ and$\mspace{6mu}\lambda^{m\alpha_{5}} = r$ and the remained eigenvalues are obtained from$$\begin{array}{ccl}
 & & {\lambda^{m{({\alpha_{2} + \alpha_{3}})}} + u\lambda^{m\alpha_{2}}} \\
 & & {\quad + \left( {\rho + \omega} \right)\lambda^{m\alpha_{3}} + \left( {u + \sigma C} \right)\left( {\rho + \omega + \delta C} \right)\left\lbrack {R_{1} - R_{0}} \right\rbrack = 0} \\
\end{array}$$where *R* ~0~ and *R* ~1~ are in [Eqs. (16)](#eqn0016){ref-type="disp-formula"}. In here, $\lambda^{m\alpha_{5}}$ is positive real number according to Ineqs [(15)](#eqn0015){ref-type="disp-formula"}. Considering De-Moivre formulas, the roots of $\lambda^{m\alpha_{5}}$ are obtained from$$\lambda_{n} = \sqrt[{m\alpha_{5}}]{r}cis\left( \frac{2\left( {n + 1} \right)\pi}{m\alpha_{5}} \right)\epsilon\mathbb{R}^{+}\mspace{6mu}\text{for}\mspace{6mu} n = 0,1,2,\ldots,\left( {m\alpha_{5} - 1} \right),$$such that $cis\pi = \cos\pi + i\sin\pi,\mspace{6mu} i = \sqrt{- 1}$. Angles, \|*arg*(*λ~n~*)\|, attained from [Eq. (26)](#eqn0026){ref-type="disp-formula"} are found out as $0,\frac{2\pi}{m\alpha_{5}},\mspace{6mu}\frac{4\pi}{m\alpha_{5}},\mspace{6mu}\ldots$,$\frac{2\left( {m\alpha_{5} - 1} \right)\pi}{m\alpha_{5}}$. Clearly, these angles are not greater than $\frac{\pi}{2m}$, due to the definition of derivative-orders in [Eqs (14)](#eqn0014){ref-type="disp-formula"}. Considering Ineqs. [(9)](#eqn0009){ref-type="disp-formula"}, the stability condition is not supplied. Therefore, *E* ~0~ is unstable point.iLet *R* ~0~ \> *R* ~1~. In this case, $E_{1}({\frac{\gamma R_{1}}{R_{0}\rho},\frac{\gamma\left( {R_{0} - R_{1}} \right)}{R_{0}\left( {\rho + \omega} \right)},\frac{\rho\left( {R_{0} - R_{1}} \right)}{\beta\left( {1 - \epsilon_{RT}} \right)R_{1}},}$ ${\frac{\gamma k\epsilon_{PI}\left( {R_{0} - R_{1}} \right)}{R_{0}u\left( {\rho + \omega} \right)},0})$ exists. When *E* ~1~ is calculated in [Eq. (25)](#eqn0025){ref-type="disp-formula"}, the eigenvalues are obtained from the equations given as $\lambda^{m\alpha_{4}} = - u$ and $\lambda^{m\alpha_{5}} = r$ and the following determinant:$$\left| \begin{matrix}
{\lambda^{m\alpha_{1}} + \left( {\rho\left( {\frac{R_{0}}{R_{1}} - 1} \right) + \rho} \right)} & 0 & \frac{\gamma\left( {1 - \epsilon_{RT}} \right)\beta}{\rho\frac{R_{0}}{R_{1}}} \\
{- \rho\left( {\frac{R_{0}}{R_{1}} - 1} \right)} & {\lambda^{m\alpha_{2}} + \left( {\rho + \omega} \right)} & {- \frac{\gamma\left( {1 - \epsilon_{RT}} \right)\beta}{\rho\frac{R_{0}}{R_{1}}}} \\
0 & {- \left( {1 - \epsilon_{PI}} \right)k} & {\lambda^{m\alpha_{3}} + u} \\
\end{matrix} \right| = 0,$$where *R* ~0~ and *R* ~1~ are in [Eqs. (16)](#eqn0016){ref-type="disp-formula"}. There is the similar state to the unstability of *E* ~0~, because $\lambda^{m\alpha_{5}}$ is positive real number. In this case, *E* ~1~ is unstable point.iBy [Eq. (25)](#eqn0025){ref-type="disp-formula"} evaluated at $E_{2}\left( {\frac{\gamma}{\rho},0,0,0,C} \right)$, the eigenvalues obtain from the following equations: $\lambda^{m\alpha_{1}} = - \rho,\lambda^{m\alpha_{4}} = - \left( {u + \sigma C} \right)$, $\lambda^{m\alpha_{5}} = - r$ and$$\begin{array}{ccl}
 & & {\lambda^{m{({\alpha_{2} + \alpha_{3}})}} + \left( {u + \sigma C} \right)\lambda^{m\alpha_{2}} + \left( {\left( {\rho + \omega} \right) + \delta C} \right)\lambda^{m\alpha_{3}} + \left( {u + \sigma C} \right)} \\
 & & {\quad \times \,\left( {\left( {\rho + \omega} \right) + \delta C} \right)\left( {1 - R_{0}} \right) = 0,} \\
\end{array}$$where *R* ~0~ is in [Eqs. (16)](#eqn0016){ref-type="disp-formula"}. It is clearly that $\lambda^{m\alpha_{1}},\lambda^{m\alpha_{4}},\mspace{6mu}\lambda^{m\alpha_{5}}\epsilon\mathbb{R}^{-}$ in accordance with Ineqs [(15)](#eqn0015){ref-type="disp-formula"}. By De-Moivre formulas, we have$$\begin{array}{lc}
{\lambda_{n_{1}} = \sqrt[{m\alpha_{1}}]{\rho}cis\frac{\left( {2n_{1} + 1} \right)\pi}{m\alpha_{1}}} & {\text{for}\mspace{6mu} n_{1} = 0,1,\ldots,\left( {m\alpha_{1} - 1} \right)} \\
{\lambda_{n_{2}} = \sqrt[{m\alpha_{4}}]{\left( {u + \sigma C} \right)}cis\frac{\left( {2n_{2} + 1} \right)\pi}{m\alpha_{4}}} & {\text{for}\mspace{6mu} n_{2} = 0,1,\ldots,\left( {m\alpha_{4} - 1} \right)} \\
{\lambda_{n_{3}} = \sqrt[{m\alpha_{5}}]{r}cis\frac{\left( {2n_{3} + 1} \right)\pi}{m\alpha_{5}}} & {\text{for}\mspace{6mu} n_{3} = 0,1,\ldots,\left( {m\alpha_{5} - 1} \right)} \\
\end{array}$$such that $cis\pi = \cos\pi + i\sin\pi,\mspace{6mu} i = \sqrt{- 1}$. Angles given as $|{arg\left( \lambda_{n_{1}} \right)}\left| = \right.\frac{\pi}{m\alpha_{1}},\frac{3\pi}{m\alpha_{1}},\ldots$so on, $|{arg\left( \lambda_{n_{2}} \right)}\left| = \right.\frac{\pi}{m\alpha_{4}},\frac{3\pi}{m\alpha_{4}},\ldots$so on and $|{arg\left( \lambda_{n_{3}} \right)}\left| = \right.\frac{\pi}{m\alpha_{5}},\frac{3\pi}{m\alpha_{5}},\ldots$so on, are greater than $\frac{\pi}{2m}$, due to the definition of derivative-orders in [Eqs (14)](#eqn0014){ref-type="disp-formula"}. In this respect, the stability conditions of *E* ~2~ for these eigenvalues do not deteriorate according to Ineqs. [(9)](#eqn0009){ref-type="disp-formula"}. Accordingly, the roots of [Eq. (27)](#eqn0027){ref-type="disp-formula"} must be examined. Let\'s remember Descartes' rule of sign [@bib0059]. If$$R_{0} < 1,$$then all coefficients of [Eq. (27)](#eqn0027){ref-type="disp-formula"} are positive real number according to Ineqs. [(15)](#eqn0015){ref-type="disp-formula"} and [(17)](#eqn0017){ref-type="disp-formula"}. [Eq. (27)](#eqn0027){ref-type="disp-formula"} has no positive root, since the sign change number of its coefficients is zero. In this sense, [Eq. (27)](#eqn0027){ref-type="disp-formula"} have not positive real root, and so, the roots of this equation are composed of negative real numbers and/or complex conjugate numbers. To show the stability of *E* ~2~, these roots are examined according to Ineqs. [(9)](#eqn0009){ref-type="disp-formula"}.

As a consequence, we have the following results:•Let *α* ~2~ ≠ *α* ~3~ \< 1. If eigenvalues obtained from [Eq. (27)](#eqn0027){ref-type="disp-formula"} have met conditions given as$$\left| {arg\left( \lambda_{n} \right)} \right| > \frac{\pi}{2m}\mspace{6mu} for\mspace{6mu} n = 1,2,\ldots,\mspace{6mu} m\left( {\mspace{6mu}\alpha_{2} + \alpha_{3}} \right),$$and Ineq. [(29)](#eqn0029){ref-type="disp-formula"} is satisfied, then infection-free equilibrium point $E_{2}\left( {\frac{\gamma}{\rho},0,0,0,C} \right)$ is asymptotically stable.•Let $\alpha_{2} = \alpha_{3} = \alpha \leq 1$. When [Eq. (27)](#eqn0027){ref-type="disp-formula"} is regulated to [Eq. (12)](#eqn0012){ref-type="disp-formula"}, the characteristic equation is obtained as$$\begin{array}{ccl}
 & & {\lambda^{2} + \left( {\left( {\left( {\rho + \omega} \right) + \delta C} \right) + \left( {u + \sigma C} \right)} \right)\lambda} \\
 & & {\quad + \,\left( {u + \sigma C} \right)\left( {\left( {\rho + \omega} \right) + \delta C} \right)\left( {1 - \mspace{6mu} R_{0}} \right) = 0} \\
\end{array}$$

According to $n = 2$ in Ineqs [(13)](#eqn0013){ref-type="disp-formula"}, it is$$\begin{array}{l}
{a_{1} = \left( {\left( {\rho + \omega} \right) + \delta C} \right) + \left( {u + \sigma C} \right)} \\
{a_{2} = \left( {u + \sigma C} \right)\left( {\left( {\rho + \omega} \right) + \delta C} \right)\left( {1 - R_{0}} \right).} \\
\end{array}$$

Considering Ineqs [(15)](#eqn0015){ref-type="disp-formula"}, if Ineq. [(29)](#eqn0029){ref-type="disp-formula"} is satisfied, then it is clear that *a* ~1~ \> 0 and *a* ~2~ \> 0. The eigenvalues of [Eq. (31)](#eqn0031){ref-type="disp-formula"} either are the negative real number or the complex number with negative real parts (Routh-Hurwitz Criteria). Consequently, *E* ~2~ is asymptotically stable in terms of [Lemma 2.1](#enun0006){ref-type="statement"}-i.iLastly, let$$R_{0} > 1.$$

In this case, $E_{3}\left( {\frac{\gamma}{\rho}\frac{1}{R_{0}},\frac{\gamma\left( {1 - \frac{1}{R_{0}}} \right)}{\left\lbrack {\left( {\rho + \omega} \right) + \delta C} \right\rbrack},\frac{\rho\left( {R_{0} - 1} \right)}{\beta\left( {1 - \epsilon_{RT}} \right)},\frac{\rho\epsilon_{PI}\left( {R_{0} - 1} \right)}{\beta\left( {1 - \epsilon_{RT}} \right)\left( {1 - \epsilon_{PI}} \right)},C} \right)$ exists. When [Eq. (25)](#eqn0025){ref-type="disp-formula"} is evaluated at this equilibrium point, the eigenvalues are obtained from the following equation:$$\begin{array}{r}
{\left( {\lambda^{m\alpha_{4}} + \left( {u + \sigma C} \right)} \right)\left( {\lambda^{m\alpha_{5}} + r} \right)\left| \begin{matrix}
\left( {\lambda^{m\alpha_{1}} + \rho R_{0}} \right) & 0 & \frac{\gamma\beta\left( {1 - \epsilon_{RT}} \right)}{\rho R_{0}} \\
{- \rho\left( {R_{0} - 1} \right)} & \left( {\lambda^{m\alpha_{2}} + \left( {\left( {\rho + \omega} \right) + \delta C} \right)} \right) & {- \frac{\gamma\beta\left( {1 - \epsilon_{RT}} \right)}{\rho R_{0}}} \\
0 & {- \left( {1 - \epsilon_{PI}} \right)k} & \left( {\lambda^{m\alpha_{3}} + \left( {u + \sigma C} \right)} \right) \\
\end{matrix} \right| = 0\mspace{25060mu}} \\
\end{array}$$where *R* ~0~ is in [Eqs. (16)](#eqn0016){ref-type="disp-formula"}. Therefore, some of the eigenvalues is acquired from $\lambda^{m\alpha_{4}} = - \left( {u + \sigma C} \right)$ and $\lambda^{m\alpha_{5}} = - r$. Considering Ineqs [(15)](#eqn0015){ref-type="disp-formula"}, we have $\lambda^{m\alpha_{4}},\mspace{6mu}\lambda^{m\alpha_{5}}\epsilon\mathbb{R}^{-}$. That eigenvalues $\lambda^{m\alpha_{4}}$ and $\lambda^{m\alpha_{5}}$ does not influence the stability conditions of *E* ~3~, is previously stated through De-Moivre formulas. Accordingly, we have the following characteristic equation:$$\begin{array}{l}
{\lambda^{m{({\alpha_{1} + \alpha_{2} + \alpha_{3}})}} + \left( {u + \sigma C} \right)\lambda^{m{({\alpha_{1} + \alpha_{2}})}} + \left( {\left( {\rho + \omega} \right) + \delta C} \right)\lambda^{m{({\alpha_{1} + \alpha_{3}})}} +} \\
{\rho R_{0}\lambda^{m{({\alpha_{2} + \alpha_{3}})}} + \rho R_{0}\left( {u + \sigma C} \right)\lambda^{m\alpha_{2}} + \left( {\left( {\rho + \omega} \right) + \delta C} \right)\rho R_{0}\lambda^{m\alpha_{3}} +} \\
{+ \rho\left( {R_{0} - 1} \right)\left( {u + \sigma C} \right)\left( {\rho + \omega + \delta C} \right) = 0} \\
\end{array}$$obtained from determinant in [Eq. (34)](#eqn0034){ref-type="disp-formula"}. Considering Ineqs. [(15)](#eqn0015){ref-type="disp-formula"}, [(17)](#eqn0017){ref-type="disp-formula"} and [(33)](#eqn0033){ref-type="disp-formula"}, the signs of the coefficients of [Eq. (35)](#eqn0035){ref-type="disp-formula"} are $+ + + + + + +$, respectively. According to Descartes' rule of sign, these eigenvalues are not compose of positive real numbers, since the change number of these signs is zero. Thus, eigenvalues consist of negative real numbers and/or complex conjugate numbers. To show the stability of *E* ~3~, it must be demonstrated that the eigenvalues achieved through [Eq. (35)](#eqn0035){ref-type="disp-formula"} provide Ineqs [(9)](#eqn0009){ref-type="disp-formula"}.

Consequently, we obtain the following results:•Let *α* ~1~ ≠  *α* ~2~ ≠ *α* ~3~ \< 1. If the eigenvalues obtained from [Eq. (35)](#eqn0035){ref-type="disp-formula"} meet the conditions given as$$\left| {arg\left( \lambda_{n} \right)} \right| > \frac{\pi}{2m}\mspace{6mu}\text{for}\mspace{6mu} n = 1,2,\ldots,\mspace{6mu} m\left( {\alpha_{1} + \alpha_{2} + \alpha_{3}} \right),$$then *E* ~3~ is asymptotically stable.•Let $\alpha_{1} = \mspace{6mu}\alpha_{2} = \alpha_{3} = \alpha \leq 1$. If [Eq. (35)](#eqn0035){ref-type="disp-formula"} regulated with respect to [Eq. (12)](#eqn0012){ref-type="disp-formula"}, it is found the following characteristic equation:$$\lambda^{3} + a_{1}\lambda^{2} + a_{2}\lambda + a_{3} = 0$$where $a_{1} = \left( {\left( {\rho + \omega + \delta C} \right) + \left( {u + \sigma C} \right) + \rho R_{0}} \right)$, $a_{2} = \rho R_{0}\left( {\left( {\rho + \omega + \delta C} \right) + \left( {u + \sigma C} \right)} \right)$ and $a_{3} = \rho\left( {R_{0} - 1} \right)\left( {u + \sigma C} \right)\left( {\rho + \omega + \delta C} \right)$. In [Eq. (37)](#eqn0037){ref-type="disp-formula"}, it is *a* ~1~, *a* ~2~, *a* ~3~ \> 0, due to Ineqs. [(15)](#eqn0015){ref-type="disp-formula"}, [(17)](#eqn0017){ref-type="disp-formula"} and [(33)](#eqn0033){ref-type="disp-formula"}. On the other hand, it is$$\begin{array}{r}
{\begin{array}{l}
{a_{1}a_{2} - a_{3} =} \\
{\rho\left\lbrack {\begin{pmatrix}
{\left( {\rho + \omega + \delta C} \right)^{2} + \left( {u + \sigma C} \right)^{2} +} \\
{\left( {\rho + \omega + \delta C} \right)\left( {u + \sigma C} \right)} \\
\end{pmatrix}R_{0} + \rho{R_{0}}^{2}\begin{pmatrix}
{\left( {\rho + \omega + \delta C} \right) +} \\
\left( {u + \sigma C} \right) \\
\end{pmatrix}\mspace{6mu} + \left( {u + \sigma C} \right)\left( {\rho + \omega + \delta C} \right)} \right\rbrack} \\
\end{array}\mspace{29810mu}} \\
\end{array}$$and $a_{1}a_{2} - a_{3} > 0$. In accord with $n = 3\mspace{6mu}$in Ineqs [(13)](#eqn0013){ref-type="disp-formula"}, all eigenvalues of [Eq. (37)](#eqn0037){ref-type="disp-formula"} are either negative real numbers or complex numbers having negative real parts. As a result, *E* ~3~ is asymptotically stable.

The proof is accomplished. The obtained results about stability analysis sum up briefly in [Table 2](#tbl0002){ref-type="table"} .Table 2The existence and asymptotically stable conditions for infection-free and endemic equilibrium points of [Eqs. (14)](#eqn0014){ref-type="disp-formula"}.Table 2Equilibrium PointNamelyThe Existence ConditionThe Asymptotically Stable Condition*E*~2~Infection-free equilibrium pointAlwaysIn case of $\mathbf{\alpha}_{2} = \mathbf{\alpha}_{3}$In other casesIf *R*~0~ \< 1,If *R*~0~ \< 1 and [Eq. (27)](#eqn0027){ref-type="disp-formula"} meet conditions Ineqs [(30)](#eqn0030){ref-type="disp-formula"},*E*~3~Endemic equilibrium point*R*~0~ \> 1In case of $\mathbf{\alpha}_{1} = \mspace{6mu}\mathbf{\alpha}_{2} = \mathbf{\alpha}_{3}$In other casesStable point.If [Eq. (35)](#eqn0035){ref-type="disp-formula"} meet conditions Ineqs [(36)](#eqn0036){ref-type="disp-formula"},

4.1. Qualitative analysis results and discussion {#sec0005}
------------------------------------------------

For the proposed model in this study, the possible stable equilibrium point is either infection-free equilibrium point *E* ~2~ or endemic equilibrium point *E* ~3~. Also, it is clear that these two equilibrium points are not stable under the same conditions according to [Table 2](#tbl0002){ref-type="table"}. While the equilibrium point *E* ~2~ represents the state in which an individual is free of viral particles, the equilibrium point *E* ~3~ shows the state in which an individual continues to fight viral particles. In this sense, the infected individual heals or the infection continues.

Considering the derivative-orders of [Eqs. (14)](#eqn0014){ref-type="disp-formula"}, the rational numbers *α* ~1~, *α* ~2~, *α* ~3~, *α* ~4~ and *α* ~5~ are derivative-orders in the system of time-dependent variables *x*(*t*), *y*(*t*), *v~I~*(*t*), *v~NI~*(*t*) and *z*(*t*), respectively.

Provided that *R* ~0~ is less than one, the stability of infection-free equilibrium point varies only depending on whether the derivative orders *α* ~2~ and *α* ~3~ are equal or not. In this sense, the infection-free status depends on the derivative-orders of equations expressing the population size of infected cells of host and the infectious viral particle concentration in the proposed model. In case of $\alpha_{2} = \alpha_{3}$ **,** infection-free equilibrium point is stable and in case of *α* ~2~ ≠ *α* ~3~ **,** if [Eq. (27)](#eqn0027){ref-type="disp-formula"} meet Ineqs [(30)](#eqn0030){ref-type="disp-formula"}, it is stable.

Let\'s assume that *R* ~0~ is greater than one. In this case, endemic equilibrium point *E* ~3~ exists. The stability of this point varies depending on the states $\alpha_{1} = \mspace{6mu}\alpha_{2} = \alpha_{3}$ and *α* ~1~ ≠  *α* ~2~ ≠ *α* ~3~. In this context, the endemic infection status depends on the derivative-orders of equations expressing the population sizes of uninfected and infected cells of host and the infectious viral particle concentration in the proposed model. This point is stable in case of $\alpha_{1} = \mspace{6mu}\alpha_{2} = \alpha_{3}$, and it is stable if [Eq. (35)](#eqn0035){ref-type="disp-formula"} meet Ineqs [(36)](#eqn0036){ref-type="disp-formula"} in case of *α* ~1~ ≠  *α* ~2~ ≠ *α* ~3~.

5. Numerical simulation of the proposed *HIV* model {#sec0006}
===================================================

To support the results of the qualitative analysis of the proposed *HIV* infection model in [Eqs. (14)](#eqn0014){ref-type="disp-formula"}, we have given numerical illustrations here. The parameter values used in model for numerical study are given in [Table 3](#tbl0003){ref-type="table"} .    Table 3Parameter values used in the numerical simulations of the optimal control for [Eqs. (14)](#eqn0014){ref-type="disp-formula"}.Table 3NotationValueReference*γ*$10^{4}\mspace{6mu} ml^{- 1}\text{da}y^{- 1}$[@bib0060]*ρ*$0.01\mspace{6mu}\text{da}y^{- 1}$[@bib0060]*β*$0.000024\mspace{6mu} ml^{- 1}\text{da}y^{- 1}$[@bib0029]$\epsilon_{RT}$0.1\* and 0.8^⁎⁎^Assumed$\epsilon_{PI}$0.1\* and 0.8^⁎⁎^Assumed*ω*$0.025\mspace{6mu}\text{da}y^{- 1}$\[[@bib0034],[@bib0060]\]*δ*$0.5{\mspace{6mu}\text{ml}}.\text{da}y^{- 1}$[@bib0060]*k*$10\mspace{6mu}\text{da}y^{- 1}$[@bib0029]*u*$2.4\mspace{6mu}\text{da}y^{- 1}$[@bib0029]*σ*$0.0001{\mspace{6mu}\text{ml}}.\text{da}y^{- 1}$Assumed*r*$0.6\mspace{6mu}\text{da}y^{- 1}\mspace{6mu}$[@bib0061]*C*3 ml\* and 10 ml^⁎⁎^Assumed$\left\lbrack \alpha_{i} \right\rbrack = \left\lbrack {\alpha_{1}\mspace{6mu}\alpha_{2}\mspace{6mu}\alpha_{3}\mspace{6mu}\alpha_{4}\mspace{6mu}\alpha_{5}} \right\rbrack$$\left\lbrack {\frac{4}{5}\mspace{6mu}\frac{4}{5}\mspace{6mu}\frac{4}{5}\mspace{6mu}\frac{19}{20}\mspace{6mu}\frac{9}{10}} \right\rbrack^{*},\left\lbrack {\frac{1}{2}\mspace{6mu}\frac{3}{4}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{19}{20}\mspace{6mu}\frac{9}{10}} \right\rbrack^{*}$*,*$\left\lbrack {\frac{8}{9}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{19}{20}\mspace{6mu}\frac{9}{10}} \right\rbrack^{**}\mspace{6mu}\left\lbrack {\frac{1}{2}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{19}{20}\mspace{6mu}\frac{9}{10}} \right\rbrack^{**}$Assumed[^1][^2][^3]

**Numerical Study 1:** From [Table 3](#tbl0003){ref-type="table"}, the basic reproduction rate *R* ~0~ is calculated as 52.762. Also, infection-free equilibrium point and endemic equilibrium point are found as *E* ~2~(10^6^, 0, 0, 0, 3) and $E_{3}\left( {1.8953e + 04,6.3912e + 03,2.3964e + 04,2.6627e + 03,3} \right)$, respectively. It is clear that *R* ~0~ \> 1. According to [Table 2](#tbl0002){ref-type="table"}, *E* ~3~ exists and *E* ~2~ is unstable point. Therefore, it can only be examined whether *E* ~3~ is stable or not.a)Let $\left\lbrack \alpha_{i} \right\rbrack = \left\lbrack {\frac{4}{5}\mspace{6mu}\frac{4}{5}\mspace{6mu}\frac{4}{5}\mspace{6mu}\frac{19}{20}\mspace{6mu}\frac{9}{10}} \right\rbrack$ for $i = 1,2,\ldots,5$. Because $\alpha_{1} = \mspace{6mu}\alpha_{2} = \alpha_{3}$, *E* ~3~ is asymptotically stable in terms of [Table 2](#tbl0002){ref-type="table"}. [Fig. 4](#fig0004){ref-type="fig"} shows this situation.Fig. 4According to $\left\lbrack \alpha_{i} \right\rbrack = \left\lbrack {\frac{4}{5}\mspace{6mu}\frac{4}{5}\mspace{6mu}\frac{4}{5}\mspace{6mu}\frac{19}{20}\mspace{6mu}\frac{9}{10}} \right\rbrack$ for $i = 1,2,\ldots,5$, the temporary trajectory of population sizes of the variables in [Eqs. (14)](#eqn0014){ref-type="disp-formula"} with initial conditions (1000, 10, 1000, 100, 2) for values\* in [Table 3](#tbl0003){ref-type="table"}.Fig 4b)Let $\left\lbrack \alpha_{i} \right\rbrack = \left\lbrack {\frac{1}{2}\mspace{6mu}\frac{3}{4}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{19}{20}\mspace{6mu}\frac{9}{10}} \right\rbrack$ for $i = 1,2,\ldots,5$. In here, it is *α* ~1~ ≠  *α* ~2~ ≠ *α* ~3~. Also, it is $m = 8$, which is the smallest of the common multiples of the denominators of rational numbers *α* ~1~, *α* ~2~ and *α* ~3~. Therefore, [Eq. (35)](#eqn0035){ref-type="disp-formula"} translates to$$\begin{array}{ccl}
 & & {\lambda^{15} + 0.5276\lambda^{11} + 2.4003\lambda^{10}} \\
 & & {\quad + \, 1.535\lambda^{9} + 1.2664\lambda^{6} + 0.8099\lambda^{5} + 1.9072 = 0.} \\
\end{array}$$

From here, the solutions for eigenvalues are given as $\lambda_{1} = - 1.0938$, $\lambda_{2} = - 0.9390\mspace{6mu} + \mspace{6mu} 0.3856i$, $\lambda_{3} = - 0.9390\mspace{6mu} - \mspace{6mu} 0.3856i$, $\lambda_{4} = - 0.6817\mspace{6mu} + \mspace{6mu} 0.7612i$, $\lambda_{5} = - 0.6817\mspace{6mu} - \mspace{6mu} 0.7612i$, $\lambda_{6} = - 0.2719\mspace{6mu} + \mspace{6mu} 1.1668i$, $\lambda_{7} = \mspace{6mu} - 0.2719\mspace{6mu} - \mspace{6mu} 1.1668i$, $\lambda_{8} = \mspace{6mu} - 0.0480\mspace{6mu} + \mspace{6mu} 0.9273i$, $\lambda_{9} = - 0.0480\mspace{6mu} - \mspace{6mu} 0.9273i$, $\lambda_{10} = 1.0688\mspace{6mu} + \mspace{6mu} 0.7239i$, $\lambda_{11} = 1.0688\mspace{6mu} - \mspace{6mu} 0.7239i$, $\lambda_{12} = 0.5729\mspace{6mu} + \mspace{6mu} 0.7876i$, $\lambda_{13} = 0.5729\mspace{6mu} - \mspace{6mu} 0.7876i$, $\lambda_{14} = 0.8458\mspace{6mu} + \mspace{6mu} 0.3362i$ and $\lambda_{15} = 0.8458\mspace{6mu} - \mspace{6mu} 0.3362i$ for $i = \sqrt{- 1}$. It is satisfied Ineqs [(36)](#eqn0036){ref-type="disp-formula"} due to *Re*{*λ~j~*} \< 0 for $j = 1,2,\ldots,9$. Thus, eigenvalues *λ~j~* do not impair the stability conditions of *E* ~3~. In addition that, $arg\left\{ \lambda_{10} \right\} = {33.94^{0}}$, $arg\left\{ \lambda_{11} \right\} = {326.06^{0}}$, $arg\left\{ \lambda_{12} \right\} = {54.19^{0}}$, $arg\left\{ \lambda_{13} \right\} = {305.81^{0}}$, $arg\left\{ \lambda_{14} \right\} = {21.80^{0}}$ and $arg\left\{ \lambda_{15} \right\} = {338.20^{0}}$. Considering Ineqs [(36)](#eqn0036){ref-type="disp-formula"}, it is $|{arg\left( \lambda_{k} \right)}\left| > \right.\frac{\pi}{2m} = \frac{\pi}{16} = {11.25^{0}}{\mspace{6mu}\text{for}\mspace{6mu}}k = 10,11,\ldots,15$. As a result, the endemic equilibrium point *E* ~3~ is asymptotically stable with respect to [Table 2](#tbl0002){ref-type="table"}. This situation is observed in [Fig. 5](#fig0005){ref-type="fig"} .Fig. 5According to $\left\lbrack \alpha_{i} \right\rbrack = \left\lbrack {\frac{1}{2}\mspace{6mu}\frac{3}{4}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{19}{20}\mspace{6mu}\frac{9}{10}} \right\rbrack$ for $i = 1,2,\ldots,5$, the temporary trajectory of population sizes of the variables in [Eqs. (14)](#eqn0014){ref-type="disp-formula"} with initial conditions (1000, 10, 1000, 100, 2) for values\* in [Table 3](#tbl0003){ref-type="table"}.Fig 5

**Numerical Study 2:** Lastly, the values of the basic reproductive ratio and the equilibrium point are calculated as $R_{0} = 0.794$ and *E* ~2~(10^6^, 0, 0, 0, 10), respectively. Considering [Table 2](#tbl0002){ref-type="table"}, *E* ~3~ is not exists due to *R* ~0~ \< 1. Consequently, only the *E* ~2~ point can or not be stable according to the different states of the derivative-orders in [Eqs. (14)](#eqn0014){ref-type="disp-formula"}.a)Let $\left\lbrack \alpha_{i} \right\rbrack = \left\lbrack {\frac{8}{9}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{19}{20}\mspace{6mu}\frac{9}{10}} \right\rbrack$ for $i = 1,2,\ldots,5$. Because *R* ~0~ \< 1 and $\alpha_{2} = \alpha_{3}$, *E* ~2~ is asymptotically stable in terms of [Table 2](#tbl0002){ref-type="table"}. This situation shows in [Fig. 6](#fig0006){ref-type="fig"}, [Fig. 7](#fig0007){ref-type="fig"} .Fig. 6According to $\left\lbrack \alpha_{i} \right\rbrack = \left\lbrack {\frac{8}{9}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{19}{20}\mspace{6mu}\frac{9}{10}} \right\rbrack$ for $i = 1,2,\ldots,5$, the temporary trajectory of population sizes of uninfected cells in [Eqs. (14)](#eqn0014){ref-type="disp-formula"} with initial conditions (1000, 10, 100, 100, 2) for values\*\* in [Table 3](#tbl0003){ref-type="table"}.Fig 6Fig. 7According to $\left\lbrack \alpha_{i} \right\rbrack = \left\lbrack {\frac{8}{9}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{19}{20}\mspace{6mu}\frac{9}{10}} \right\rbrack$ for $i = 1,2,\ldots,5$, the temporary trajectory of population sizes of the variables exceptly uninfected cells in [Eqs. (14)](#eqn0014){ref-type="disp-formula"} with initial conditions (1000, 10, 100, 100, 2) for values\*\* in [Table 3](#tbl0003){ref-type="table"}.Fig 7b)Lastly, let us consider as $\left\lbrack \alpha_{i} \right\rbrack = \left\lbrack {\frac{1}{2}\mspace{6mu}\frac{3}{4}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{19}{20}\mspace{6mu}\frac{9}{10}} \right\rbrack$ for $i = 1,2,\ldots,5$. In here, it is *α* ~2~ ≠  *α* ~3~. Because $\alpha_{2} = \frac{3}{4}$ and $\alpha_{3} = \frac{5}{8}$, it is $m = 8$. [Eq. (27)](#eqn0027){ref-type="disp-formula"} translates to$$\lambda^{11} + 2.401\lambda^{6} + 5.035\lambda^{5} + 2.489 = 0.$$

Therefore, we obtain that $\lambda_{1} = - 0.1138 + 1.3105i$, $\lambda_{2} = - 0.1138 - 1.3105i$, $\lambda_{3} = - 1.0763 + 0.5670i$, $\lambda_{4} = - 1.0763 - 0.5670i$, $\lambda_{5} = - 0.9362$, $\lambda_{6} = - 0.2140 + 0.8523i$, $\lambda_{7} = - 0.2140 - 0.8523i$, $\lambda_{8} = 1.1893 + 0.7449i$, $\lambda_{9} = 1.1893 - 0.7449i$, $\lambda_{10} = 0.6829 + 0.4651i$ and $\lambda_{11} = 0.6829 - 0.4651i$. Since *Re*{*λ~j~*} \< 0 for $j = 1,2,\ldots,7$ and $arg\left\{ \lambda_{8} \right\} = {31.88^{0}}$, $arg\left\{ \lambda_{9} \right\} = {328.12^{0}}$, $arg\left\{ \lambda_{10} \right\} = {34.65^{0}}$ and $arg\left\{ \lambda_{11} \right\} = {325.35^{0}}$, we have $|{arg\left( \lambda_{k} \right)}\left| > \right.\frac{\pi}{2m} = \frac{\pi}{16} = {11.25^{0}}{\mspace{6mu}\text{for}\mspace{6mu}}k = 1,2,\ldots,11$. According to [Table 2](#tbl0002){ref-type="table"}, *E* ~2~ is asymptotically stable as seen [Fig. 8](#fig0008){ref-type="fig"}, [Fig. 9](#fig0009){ref-type="fig"} .Fig. 8According to $\left\lbrack \alpha_{i} \right\rbrack = \left\lbrack {\frac{1}{2}\mspace{6mu}\frac{3}{4}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{19}{20}\mspace{6mu}\frac{9}{10}} \right\rbrack$ for $i = 1,2,\ldots,5$, the temporary trajectory of population sizes of the variables in [Eqs. (14)](#eqn0014){ref-type="disp-formula"} with initial conditions (1000, 10, 1000, 100, 2) for values\*\* in [Table 3](#tbl0003){ref-type="table"}.Fig 8Fig. 9According to $\left\lbrack \alpha_{i} \right\rbrack = \left\lbrack {\frac{1}{2}\mspace{6mu}\frac{3}{4}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{19}{20}\mspace{6mu}\frac{9}{10}} \right\rbrack$ for $i = 1,2,\ldots,5$, the temporary trajectory of population sizes of the variables in [Eqs. (14)](#eqn0014){ref-type="disp-formula"} with initial conditions (1000, 10, 1000, 100, 2) for values\*\* in [Table 3](#tbl0003){ref-type="table"}.Fig 9

5.1. Numerical simulation results and discussion {#sec0007}
------------------------------------------------

In this part, we have given some numerical simulations for the presented model in [Eqs. (14)](#eqn0014){ref-type="disp-formula"}. For this model, we used the values of biological parameters and derivative-orders from [Table 3](#tbl0003){ref-type="table"} (Values \* and \*\*), and so the dynamics of [Eqs. (14)](#eqn0014){ref-type="disp-formula"} with different initial conditions (*x* ~0~, *y* ~0~, *v~I~* ~0~, *v~NI~* ~0~, *z* ~0~) are plotted in [Fig. 4](#fig0004){ref-type="fig"}, [Fig. 5](#fig0005){ref-type="fig"}, [Fig. 6](#fig0006){ref-type="fig"}, [Fig. 7](#fig0007){ref-type="fig"}, [Fig. 8](#fig0008){ref-type="fig"}, [Fig. 9](#fig0009){ref-type="fig"}. Two different numerical studies have been done by using the values of [Table 3](#tbl0003){ref-type="table"}. In this sense, different scenarios have been tried to be obtained.

In the first study, the values indicated by \*, where $\epsilon_{RT} = \epsilon_{PI} = 0.1$ and $C = 3\mspace{6mu}\text{ml}$, are used. While infection-free equilibrium point *E* ~2~(10^6^, 0, 0, 0, 3) always exists, endemic equilibrium point $E_{3}\left( {1.8953e + 04,6.3912e + 03,2.3964e + 04,2.6627e + 03,3} \right)$ biologically exits due to $R_{0} = 52.762 > 1$.•For derivative-orders $\left\lbrack {\frac{4}{5}\mspace{6mu}\frac{4}{5}\mspace{6mu}\frac{4}{5}\mspace{6mu}\frac{19}{20}\mspace{6mu}\frac{9}{10}} \right\rbrack\mspace{6mu}\left( {\alpha_{1} = \mspace{6mu}\alpha_{2} = \alpha_{3}} \right)$, *E* ~3~ has been shown to meet asymptotic stability conditions for [Eqs. (14)](#eqn0014){ref-type="disp-formula"} according to [Table 2](#tbl0002){ref-type="table"}. In this context, the [Fig. 4](#fig0004){ref-type="fig"} has drawn. Approximately at least 400 days later, the infection process will approach a positive equilibria and the disease will continue endemically.•[Eqs. (14)](#eqn0014){ref-type="disp-formula"} has been considered for derivative-orders $\left\lbrack {\frac{1}{2}\mspace{6mu}\frac{3}{4}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{19}{20}\mspace{6mu}\frac{9}{10}} \right\rbrack\mspace{6mu}\left( {\alpha_{1} \neq \mspace{6mu}\alpha_{2} \neq \alpha_{3}} \right)$. As a result of providing the related conditions in [Table 2](#tbl0002){ref-type="table"}, the stability of *E* ~3~ was shown in [Fig. 5](#fig0005){ref-type="fig"}. In this sense, it was graphically represented that this endemic case would occur after at least 600 days.

In the second study, it is used the values indicated by \*\*, where $\epsilon_{RT} = \epsilon_{PI} = 0.8$ and $C = 10\mspace{6mu}\text{ml}$. Here, there is a situation where the efficacy of the therapy with reverse transcriptase inhibitors and reverse protease inhibitors is increased and the carrying capacity of *CTL* response of host is greater too. Infection-free equilibrium point and basic reproduction rate are found as *E* ~2~(10^6^, 0, 0, 0, 10) and $R_{0} = 0.794\left( < 1 \right)$, respectively.•Let us considered the derivative-orders as $\left\lbrack {\frac{8}{9}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{19}{20}\mspace{6mu}\frac{9}{10}} \right\rbrack\mspace{6mu}\left( {\alpha_{2} = \alpha_{3}} \right)$. Taking into consideration [Table 2](#tbl0002){ref-type="table"}, it is shown that *E* ~2~ meet asymptotic stability conditions, and thus [Fig. 6](#fig0006){ref-type="fig"}, [Fig. 7](#fig0007){ref-type="fig"} is drawn. In about 200 days, while infected cells and viral particles disappear, *CTL* response of host approaches its carrying capacity. On the other hand, it takes a long time for the uninfected cells to approach its equilibrium value.•Derivative-orders were considered as $\left\lbrack {\frac{1}{2}\mspace{6mu}\frac{3}{4}\mspace{6mu}\frac{5}{8}\mspace{6mu}\frac{19}{20}\mspace{6mu}\frac{9}{10}} \right\rbrack\mspace{6mu}\left( {\mspace{6mu}\alpha_{2} \neq \alpha_{3}} \right)$. In here, it was shown that the conditions related to the stability of *E* ~2~ in the [Table 2](#tbl0002){ref-type="table"} were satisfied, and it was supported by [Fig. 8](#fig0008){ref-type="fig"}, [Fig. 9](#fig0009){ref-type="fig"}. As can be seen from these figures, clearing the infection takes at least 200 days.

6. Conclusions {#sec0008}
==============

In this study, we proposed the new *HIV* model including the five time-dependent variables: the host cells as susceptible and infected, the viral particles as infectious and noninfectious and the host\'s immune system response as *CTL* cells. This model proposed in [Eqs. (14)](#eqn0014){ref-type="disp-formula"} is the form of incommensurate fractional-order nonlinear system (FOS) with the Caputo fractional derivative. In addition, the derivative-orders of these dependent variables in the system are as follows *α* ~1~, *α* ~2~, *α* ~3~, *α* ~4~ and *α* ~5~ in interval (0, 1\], respectively. Considering the *HIV* models in the literature, the main innovations in our model are follows:•We built the model by using incommensurate FOS consisting of five equations.•We have assumed that *CTL* cells of the host have the effect of destroying both infected cells and viral particles, and *CTL* cells have followed the logistic growth model.

Our model exhibits two equilibria, namely, disease-free equilibrium and the endemic equilibrium points. In general, the *HIV* models in literature trying to explain the infection process with the ONLY parameter basic reproduction rate *R* ~0~. By qualitative analysis of our model, what we found are as follows•Disease-free equilibrium point always exists and is asymptotically stable,$$\left\{ \begin{array}{lc}
{\text{If}\mspace{6mu} R_{0}\, < \, 1} & {{\text{in}\mspace{6mu}\text{case}\mspace{6mu}\text{of}}\mspace{6mu}\alpha_{2} = \alpha_{3}.} \\
{\text{If}\, R_{0}\, < 1\,\text{and}\,\left( 4.12 \right)\,{\text{meet}\,\text{conditions}\,}\!\left( 4.15\! \right)} & {{\text{in}\mspace{6mu}\text{other}\mspace{6mu}\text{cases}}.} \\
\end{array} \right.$$•Endemic equilibrium point exists when *R* ~0~ \> 1. This point is asymptotically stable,$$\left\{ \begin{array}{lc}
{\text{If}\, R_{0} > 1\left( {\text{also}\,\text{the}\,\text{existence}\,\text{condition}} \right)} & {{\text{in}\,\text{case}\,\text{of}}\,\alpha_{1}\, = \,\alpha_{2}\, = \,\alpha_{3}.} \\
{\text{If}\,\left( 4.20 \right)\,{\text{meet}\,\text{conditions}}\,\left( 4.21 \right)} & {{\text{in}\,\text{other}\,\text{cases}}.} \\
\end{array} \right.$$

We have achieved the abovementioned stability conditions that can be seen in [Table 2](#tbl0002){ref-type="table"}. To support the stability analysis results, the numerical simulations of our model have been made in the light of the parameter values taken from the literature. The obtained analysis results of model demonstrate the simplicity and the productivity of this model, when the progress of the infection is considered.

In future studies, the progress of the infection may be descripted better by considering such as the following factors:•acquiring disease through gene transfer between infected and uninfected cells,•effect of regional conditions (For example, the progression times of *HIV* between people living in Europe and African continent can vary considerably.) and•different inhibitor treatment strategies.
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[^1]: \*: Only the used value for first numerical study,

[^2]: \*\*: Only the used value for second numerical study,

[^3]: Other values are commonly used in numerical studies.
